The selection follows a seven-month formulation development program conducted by Catalent, in which the API was screened for ideal formulation conditions, with a number of potential excipients, to come up with a drug product that suits ProtoKinetix’s needs.

Catalent today announced that three of its experts will be speaking on current market trends and strategies within the industry at two upcoming conferences, Outsourcing in Clinical Trials East Asia, and Outsourcing in Clinical Trials Southern California 2021.

Catalent today announced the opening a new facility in San Diego, in response to increased demand from pharmaceutical and biopharmaceutical customers for integrated development, clinical packaging, and distribution solutions on the U.S. West Coast.

Catalent today announced a $230 million expansion project to add three further commercial-scale viral vector manufacturing suites and associated support facilities and services at its gene therapy campus in Harmans, Maryland, to meet growing customer demand.

Catalent today announced the opening of its new clinical supply facility, strategically located in the Shiga prefecture of Japan, in response to increased demand for end-to-end services, including primary packaging and white glove services.

Catalent today announced that it had signed a commercial supply agreement with Phathom Pharmaceuticals for its lead compound, vonoprazan, which is a novel, orally active-potassium competitive acid blocker (P-CAB).

Catalent today announced that it has reached an agreement to acquire Bettera Holdings, LLC, a major manufacturer in the high-growth gummy, soft chew, and lozenge segments of the nutritional supplements market, for $1 billion.

Catalent today announced the appointment of Harold A. Jenkins III, as General Manager of its recently expanded Philadelphia facility, the company’s North American center of excellence for clinical supply packaging.

Catalent has signed a commercial supply agreement with Edenbridge Pharmaceuticals, for a novel formulation of glycopyrrolate using Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) delivery technology intended for use as adjunctive therapy in the treatment of patients with peptic ulcer.